

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

VIFOR FRESENIUS MEDICAL CARE	)	
RENAL PHARMA LTD. and VIFOR	)	
(INTERNATIONAL) INC,	)	
	)	
Plaintiffs,	)	C.A. No. _____
	)	
v.	)	
	)	
CIPLA LTD.,	)	
	)	
Defendant.	)	

**SUPPLEMENTAL INFORMATION FOR PATENT CASES INVOLVING AN
ABBREVIATED NEW DRUG APPLICATION (ANDA)**

Plaintiffs Vifor Fresenius Medical Care Renal Pharma Ltd. and Vifor (International) Inc.
hereby provide the information below with respect to the deadlines set forth in 21 U.S.C.

§ 355(j):

Date Patentees Received Notice Cipla Ltd.'s Paragraph IV Notice: October 9, 2025

Dates of Patent Expiration:

- U.S. Patent No. 7,402,564: November 12, 2027, to be extended to November 12, 2032¹

Thirty-Month Stay Deadline: February 23, 2029

¹ The United States Patent and Trademark Office has made a determination that U.S. Patent No. 7,402,564 is eligible for patent term extension under 35 U.S.C. § 156, extending the expiration date from November 12, 2027 to November 12, 2032. As of the date of this filing, the corresponding Certificate of Extension has not yet issued. Upon issuance the Certificate of Extension, the expiration date of U.S. Patent No. 7,402,564 will be November 12, 2032.

Dated: November 21, 2025

QUINN EMANUEL URQUHART & SULLIVAN, LLP

s/ Jared W. Newton

Jared W. Newton (#7519)
500 Delaware Avenue, Suite 220
Wilmington, DE 19801
(302) 302-4000
jarednewton@quinnemanuel.com

OF COUNSEL:

Matthew A. Traupman
Elliot Choi
Shira M. Bergman
QUINN EMANUEL
URQUHART & SULLIVAN, LLP
295 Fifth Avenue
New York, NY 10016
(212) 849-7000

*Attorneys for Plaintiffs Vifor Fresenius Medical
Care Renal Pharma Ltd. and Vifor (International)
Inc.*